Company

About RetInSight

About RetInSight

RetInSight GmbH was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable individuals affected by retinal disease to maintain their full vision preserving quality of life and lifelong autonomy.

To this goal, we are developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to detect and monitor the following retinal diseases: Intermediate AMD, geographic atrophy (GA), neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most prevalent age-related diseases that lead to visual impairments in today’s world.

 

 


 

Our Vision

Preserve eyesight throughout lifetime

 

 


 

Our Mission

Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables efficient and economic patient management together with highest medical quality for diagnosis and monitoring in retinal diseases:
For anyone, any time and at any location, by supporting networked care in ophthalmology with the help of AI technology and digital data.

Our Story

07/2019

Prof. Dr. Ursula Schmidt-Erfurth, MUV Medical University of Vienna (Host) and Dr. Amir Sadeghipour (Fellow) receive an FFG Spin-off Fellowship Grant

04/2020

Foundation of the MUV Spin-off RetInSight by Dr. Amir Sadeghipour, Prof. Peter Schwarz and Corinna zur Bonsen-Thomas

04/2020

RetInSight commences clinical trial service business (cAIre)

12/2021

ISO 13485 Certification by TUEV SUED

05/2022

MDR CE-Certification and Commercial Launch of RetInSight Fluid Monitor

11/2023

MDR CE-Certification and Commercial Launch of RetInSight GA Monitor

12/2023

Release of Fluid Monitor Upgrade

01/2024

ISO 27001 Certification by TUEV SUED

03/2024

Consortium member of the EU-funded I-SCREEN project